Suraj Muley
Dr. Suraj Ashok Muley is a dedicated physician educator and internationally recognized expert in neuromuscular medicine and clinical neurophysiology. Currently serving as Director of Neurology at the Bob Bové Neuroscience Institute and Professor of Medicine at the Arizona State University John Shufeldt School of Medicine and Medical Engineering, Dr. Muley is committed to advancing medical education, patient care, and innovative research in autoimmune neuromuscular disorders. With over three decades of experience in clinical practice, education, and research, Dr. Muley has mentored generations of students and physicians, while pioneering treatments and clinical trial work in CIDP, GBS, MMN, and myasthenia gravis.
Education and Training
Dr. Muley received his M.B.B.S. from Seth G.S. Medical College, University of Bombay. He completed his initial training in internal medicine in Mumbai before pursuing research in pharmacology at the University of Minnesota. He completed his U.S. clinical training with an internal medicine internship at the University of North Dakota, followed by neurology residency and clinical fellowships in clinical neurophysiology and neuromuscular disorders at the University of Minnesota, under the mentorship of Drs. Gareth Parry and John Day.
Clinical Expertise and Interests
Dr. Muley’s clinical expertise lies in the diagnosis and treatment of immune-mediated neuromuscular disorders including CIDP, GBS, MMN, and myasthenia gravis. He has led nationally recognized clinical programs and served as principal investigator on over 40 major clinical trials. His clinical acumen is matched by his commitment to individualized, evidence-based patient care.
Teaching Philosophy and Approach
Dr. Muley is a passionate educator whose teaching philosophy emphasizes clinical reasoning, hands-on training, and patient-centered learning. His inclusive, inquiry-driven approach encourages students and residents to develop independent judgment, critical thinking, and humanistic values in medicine. He has directed multiple medical student and residency programs and served as a block director for foundational neuroscience and neuromuscular courses.
Research, Grants and Scholarly Interests
Dr. Muley is actively engaged in clinical research with a focus on therapeutic trials in CIDP, MG, and rare neuromuscular diseases. He has authored over 50 peer-reviewed publications and contributed chapters to major neurology textbooks. His research has helped shape treatment paradigms in IVIG, eculizumab, efgartigimod, and other targeted therapies. He continues to lead multi-center studies, with support from various sources.
Awards and Recognitions
Dr. Muley has received numerous awards for excellence in neurology education and research, including the Benjamin Shapiro Fellowship, Fulbright Senior U.S. Scholar Award, and Teacher of the Year at Barrow Neurological Institute.
Professional Memberships
Dr. Muley is a Fellow of the American Academy of Neurology (FAAN), the American College of Physicians (FACP), and the Royal College of Physicians of Edinburgh (FRCP). He is a long-standing member of the Peripheral Nerve Society and has served in leadership roles and advisory boards for national and international neuromuscular organizations.
Personal Interests
Outside of his professional commitments, Dr. Muley enjoys international travel, music, and exploring interdisciplinary collaborations in technology and medicine. He is deeply committed to mentoring the next generation of physicians and contributing to global neurological care through education and public health partnerships.
Seth G. S. Medical College, Mumbai, India, MD 1991
Neurology Residency Training, University of Minnesota, 1997
Neuromuscular Medicine & Clinical Neurophysiology Fellowship Training, University of Minnesota, 1999
Clinical research in immune mediated neuromuscular disorders (myasthenia gravis, CIDP, Guillain Barre syndrome, multifocal motor neuropathy)
HonorHealth Neuroscience Research Institute
Selected Publications:
Early deterioration of CIDP following transition from IVIG to FcRn inhibitor treatment. Todd Levine and Suraj Muley. J Neurol Sci 2024 Nov 17:123313. Doi 10.1016/j.jns.2024.123313
Editorial: Guidelines for diagnosis and treatment of CIDP, everyday application. Suraj Muley and Said Beydoun. Therapeutic Advances In Neurological Diseases, Ther Adv Neurol Disord. 2023; 16: 17562864231190549
The Use of Eculizumab in Ventilator Dependent Myasthenia Gravis Patients, Usman U, Chrisman C, Houston D, Haws C, Wang A and Muley S. Muscle and Nerve. 2021 Aug:64(2):212-215
Rituximab in refractory chronic inflammatory demyelinating polyneuropathy. Muley SA, Jacobsen B, Parry G et al. Muscle Nerve 2020 May;61(5):575-579
Immunohistochemistry and electrophysiological findings in swine abattoir workers with immune-mediated polyradiculoneuropathy. Muley SA, Holzbauer S, Clark B, Sejvar J, Lynfield R, Parry G, Devries A. J Neurol Sci. 2018 Feb 15;385:34-38
Multifocal Motor Neuropathy. Suraj Ashok Muley and Gareth Parry. J Clin Neurosci. 2012 Sep;19(9):1201-9
Inflammatory Demyelinating Neuropathies. Suraj Ashok Muley & Gareth Parry. Curr Treat Options Neurol. 2009 May;11(3):221-7.
Safety and efficacy of pulsed methylprednisolone in the treatment of chronic inflammatory demyelinating polyneuropathy. Suraj Ashok Muley and Gareth J. Parry. Arch Neurol. 2008 Nov;65(11):1460-4
Autoimmune Rippling Muscle. Suraj Ashok Muley and John Day. Neurology 2003; 61: 869.
Effects of Changes in Experimental Design on PET Studies of Isometric Force.
Suraj A. Muley, James Ashe, Stephen C. Strother, Sally A. Frutiger, John R. Anderson, John J. Sidtis and David A. Rottenberg. Neuroimage 2001;13, 185-195
Neuropathy in Erythropoietic Protoporphyrias.Suraj A. Muley, Hani Midani, Jeffrey Rank, R. Carithers, Gareth Parry. Neurology 1998 Jul;51(1):262-5
Multiple trials in immune mediated neuromuscular disorders
Selected Presentations:
Infections related safety profile of efgartigimod alfa and immunoglobulins in myasthenia gravis. Suraj Muley, Valentina Giunchi, Michele Fusaroli, Mathurin Baquie, Christoph Wissmann, Elisabetta Poluzzi, American Academy of Neurology, Platform presentation, April 2025, San Diego, CA
Treatment Burden According to Patients with Generalized Myasthenia Gravis. Katherine Ruzhansky, Neelam Goyal, Suraj Muley and Tuan Vu. Presented at AAN, Seattle 2022
Patient Burden of Generalized Myasthenia Gravis. Suraj Muley, Deborah Gelinas, Johan Sani, Katherine Ruzhansky, AANEM Poster Presentation. October 2021, Denver, CO
Outbreak of Acute Motor Axonal Neuropathy in Mexico and Southern Arizona. Shafeeq Ladha, James Sejvar, Suraj Muley. American Academy of Neurology, 2012 meeting
Serum antibodies target axons in immune-mediated polyradiculoneuropathy (IP) among swine abattoir workers exposed to aerosolized porcine brain. Suraj Ashok Muley, Stacy Holzbauer, Brent Clark, James Sejvar, Ruth Lynfield, Gareth Parry and Aaron DeVries. Presented at the AAN 2011 meeting, Honolulu, Hawaii
Pulsed Methylprednisolone in the treatment of Myasthenia Gravis. Ezgi Teryaki and Suraj Ashok Muley. Presented at the AAN 2008 meeting, Seattle, WA
Efficacy and Safety of Pulsed Oral Methylprednisolone in CIDP. Suraj Ashok Muley, Praful Kelkar and Gareth Parry. Presented at the American Academy of Neurology Meeting, April 2006, San Diego, CA
Relationship of force magnitude to brain activation during the exertion of static isometric force. S. A. Muley, J. Ashe, J. R. Anderson, S. Frutiger, S. C. Strother and D. A. Rottenberg. Presented at the Society for Neuroscience meeting in Nov. 2000, New Orleans, Louisiana in November 2000. Society of Neuroscience, Volume 26, 2000.
Changes in experimental design can make differences in patterns of brain activation during performanceof a simple motor task; Suraj Muley, James Ashe, Steve Strother, John Anderson, John Sidtis, Sally Frutiger and David Rottenberg; Will be presented at the Fifth International meeting on mapping of the Human Brain in Dusseldorf, Germany in June 1999 and published as an abstract in “Neuroimage
Minor changes in experimental design can make significant differences in patterns of brain activation during a simple motor task : a PET study. Suraj Muley, James Ashe, Steve Strother, John Anderson, John Sidtis, Sally Frutiger and David Rottenberg. (Presented at the American Academy of Neurology meeting, Toronto, April 1999)
Clinical & Electrophysiological Characteristics of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), CIDP with Monoclonal Gammopathy of Uncertain Significance and Demyelinating Neuropathy with Antibodies to Myelin Associated Glycoprotein. Suraj A. Muley, Neeraj Kumar and Gareth Parry; Neurology 50(4):P03.043. (Presented at the American Academy of Neurology meeting, Minneapolis, April 1998)
Peripheral Neuropathy in Erythropoietic Protoporphyrias. Neurology 1996; 46(2):A447. Suraj A. Muley, Hani Midani, Gareth Parry: (Presented at the American Academy of Neurology meeting, San Francisco, March 1996).
Fulbright Senior US Scholar in Neuroscience, US Department of State, 2020-21
Outstanding Service in Neurology Medical Education Award, Barrow Neurological Institute, June 2017
Neurology Teacher of the Year Award, Barrow Neurological Institute, 2010-11
Benjamin Shapiro Graduating Best Resident Award, 1996-97
Fellow, American Academy of Neurology, 2019
Fellow, American College of Physicians, 2022
Fellow, Royal College of Physicians, Edinburgh, Scotland, UK, 2024
Member, Peripheral Nerve Society, 2009
Research Mentorship – MPH Thesis, (University of Arizona), 2015
Professor of Neurology, Barrow Neurological Institute, 2009-2022
Professor of Neurology, University of Arizona, School of Medicine, 2012 to date
Associate Professor of Neurology, University of Minnesota, 2007 - 2009
Assistant Professor of Clinical Neurology, UC Davis School of Medicine, 2006-2007
Assistant Professor of Neurology, University of Minnesota, 1999-2007
Fulbright Senior Scholar in Neuroscience, 2020
Argenx, CIDP and Myasthenia Gravis
AstraZeneca, Myasthenia Gravis
Amgen, Myasthenia Gravis
Annexon, Guillain Barre Syndrome
JNJ, Myasthenia Gravis
CSL Behring, CIDP
Takeda, CIDP
Grifols, CIDP
UCB Pharma, Myasthenia Gravis